Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report

Yoshinari Endo, MD; Yusuke Inoue, MD, PhD; Masato Karayama, MD, PhD; Yasuyuki Nagata, MD. PhD; Hironao Hozumi, MD, PhD; Yuzo Suzuki, MD, PhD; Kazuki Furuhashi, MD, PhD; Noriyuki Enomoto, MD, PhD; Tomoyuki Fujisawa, MD, PhD; Yutaro Nakamura, MD, PhD; Naoki Inui, MD, PhD; Takafumi Suda, MD, PhD

JTO Clinical and Research Reports (Jan 2022)

Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report

Yoshinari Endo, MD,
Yusuke Inoue, MD, PhD,
Masato Karayama, MD, PhD,
Yasuyuki Nagata, MD. PhD,
Hironao Hozumi, MD, PhD,
Yuzo Suzuki, MD, PhD,
Kazuki Furuhashi, MD, PhD,
Noriyuki Enomoto, MD, PhD,
Tomoyuki Fujisawa, MD, PhD,
Yutaro Nakamura, MD, PhD,
Naoki Inui, MD, PhD,
Takafumi Suda, MD, PhD

Affiliations

Yoshinari Endo, MD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Yusuke Inoue, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan; Corresponding author. Address for correspondence: Yusuke Inoue, MD, PhD, Second Division, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan.
Masato Karayama, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan
Yasuyuki Nagata, MD. PhD: Third Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Hironao Hozumi, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Yuzo Suzuki, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Kazuki Furuhashi, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Noriyuki Enomoto, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Tomoyuki Fujisawa, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Yutaro Nakamura, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Naoki Inui, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan
Takafumi Suda, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

Journal volume & issue: Vol. 3, no. 1
p. 100263

Abstract

Read online

Various immune-related adverse events can frequently occur, which may be life-threatening if programmed death 1 or its ligand is blocked. Here, we report a rare case of concomitant autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis caused by atezolizumab plus chemotherapy in a patient with lung adenocarcinoma and autoantibodies. Dramatic and lasting tumor regression in response to only one therapy cycle was achieved. Nevertheless, this case suggests that careful management is required when using immunotherapy in patients with autoantibodies.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords